Scarica l'app Stockscreener
107.00
0.36%
-0.39
Dopo l'orario di chiusura:
106.76
-0.24
-0.22%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HALO Giù?
Forum
Previsione
Halozyme Therapeutics Inc Borsa (HALO) Ultime notizie
Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026 - GlobeNewswire Inc.
Alteogen Licenses ALT-B4 to Novartis in Deal Worth Up to $3.2 Billion, Reaffirming Value of SC Formulation Platform - finance.biggo.com
Halozyme at Wells Fargo healthcare conference: subQ push gains steam By Investing.com - Investing.com UK
Transcript : Halozyme Therapeutics, Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 03 - marketscreener.com
Halozyme Therapeutics (NASDAQ:HALO) Screens Well on High Growth Momentum and Breakout Setup - ChartMill
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: A Biotech Powerhouse with a Revenue Growth of 47.70% - DirectorsTalk Interviews
Biotech Stocks At 52-Week HighsATTO, HALO, IKT, TVTX, ATRC - RTTNews
Halozyme Therapeutics | SCHEDULE 13G: Others - Moomoo
Halozyme Therapeutics stock hits all-time high at 109.69 USD By Investing.com - Investing.com Nigeria
Halozyme (NASDAQ: HALO) awards board member new RSUs and options vesting at 2027 meeting - Stock Titan
Halozyme Therapeutics stock hits all-time high at 109.69 USD - Investing.com
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $115 - Moomoo
Halozyme Investor Conferences Put ENHANZE and Expanded Drug Delivery Portfolio in Focus - Yahoo Finance
Halozyme to Participate at Upcoming Investor Conferences - marketscreener.com
Three Halozyme executive talks will be webcast in September - Stock Titan
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now - Yahoo Finance
Halozyme: The Market May Be Underpricing The Second Growth Wave (NASDAQ:HALO) - Seeking Alpha
Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: A Robust Growth Trajectory in the Biotech Sector - DirectorsTalk Interviews
Zacks.com featured highlights Herbalife, Honda Motor, Marathon, Halozyme and Genworth - Yahoo Finance
Halozyme Therapeutics (HALO) Stock Trades At A Premium To Fair Value - Yahoo Finance
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen - Yahoo Finance
Halozyme Therapeutics stock hits all-time high at 109.59 USD By Investing.com - Investing.com Nigeria
Halozyme Therapeutics stock hits all-time high at 109.59 USD - Investing.com
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Strong Revenue Growth and Robust Pipeline Drive Investor Interest - DirectorsTalk Interviews
Halozyme (HALO) Stock Could Be Fully Priced On The Board Appointment - Sahm
New Halozyme (NASDAQ: HALO) director logs zero stock in first ownership filing - Stock Titan
HALO Stock Rises 36% in a Month: Here's What You Should Know - TradingView
Great Lakes Advisors LLC Purchases Shares of 36,039 Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (HALO) Adds A New Director, Is It 21% Overvalued? - Sahm
Aurora Investment Counsel Takes Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme CEO Helen Torley sells $6.28m in company shares By Investing.com - Investing.com Australia
Halozyme CEO Helen Torley sells $6.28m in company shares - Investing.com
Halozyme Therapeutics (NASDAQ:HALO) CEO Sells 20,000 Shares of Stock - MarketBeat
Halozyme (NASDAQ: HALO) CEO sells tens of thousands of shares - Stock Titan
Halozyme (HALO) Levels: Moves 2.60% Up to $107.62 in the Latest Reading; Range View: Price Remains Between $102.24 Support and $113.00 Resistance for the Current SessionInsider Buying Alerts - Vinanet
Halozyme Appoints Dannielle Appelhans to Board of Directors - The Globe and Mail
Foster & Motley Inc. Invests $2 Million in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Diversify Advisory Services LLC Invests $2.77 Million in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics Appoints Dannielle Appelhans to Board of Directors - Kalkine Media
Halozyme Therapeutics (NASDAQ:HALO): What Is Driving the Rally? - Kalkine Media
Halozyme adds Dannielle Appelhans to board of directors - Investing.com
Halozyme adds Dannielle Appelhans to board of directors By Investing.com - Investing.com Australia
Halozyme Therapeutics stock hits all-time high of 104.86 USD By Investing.com - Investing.com Australia
Halozyme Appoints Dannielle Appelhans to its Board of Directors - PR Newswire
Halozyme Therapeutics (NASDAQ:HALO) Reaches New 52-Week HighWhat's Next? - MarketBeat
Halozyme Therapeutics stock hits all-time high of 104.86 USD - Investing.com
H.C. Wainwright reiterates Halozyme stock rating on partner data By Investing.com - Investing.com Canada
HALO Q2 2026 Earnings: EPS Surges 21.75% Above Estimates, Shares Climb 4.4%New Analyst Coverage - Vinanet
Halozyme (NASDAQ: HALO) insider lines up new stock sale after recent disposals - Stock Titan
Horizon Investment Services LLC Buys Shares of 28,793 Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: A Biotech Powerhouse with Robust Revenue Growth - DirectorsTalk Interviews
Chase Investment Counsel Corp Buys New Stake in Halozyme Therapeutics, Inc. $HALO - MarketBeat
The Top 5 Analyst Questions From Halozyme Therapeutics’s Q2 Earnings Call - Yahoo Finance
Incyte Corporation (INCY) has the Bigger Revenue Base, but Could Halozyme Therapeutics, Inc. (HALO) have the Better Economics? - Yahoo Finance
Halozyme (HALO) Q2 2026 Earnings Call Transcript - The Globe and Mail
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why - Yahoo Finance
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):